Yamazaki Haruhiko, Iwasaki Hiroyuki, Yamashita Toshinari, Yoshida Tatsuya, Suganuma Nobuyasu, Yamanaka Takashi, Masudo Katsuhiko, Nakayama Hirotaka, Kohagura Kaori, Rino Yasushi, Masuda Munetaka
Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
Case Rep Endocrinol. 2018 Mar 28;2018:7875929. doi: 10.1155/2018/7875929. eCollection 2018.
A 63-year-old man was diagnosed with multiple lung metastases from anaplastic thyroid cancer and received lenvatinib. Follow-up computed tomography on day 34 of lenvatinib treatment showed pneumothorax. The pneumothorax was temporarily improved with chest drainage. However, pleurodesis was performed to treat a relapse of the pneumothorax. Pneumothorax during chemotherapy for a malignant tumor is considered a relatively rare complication. This case is the first documentation that pneumothorax may develop during lenvatinib treatment. The possible development of pneumothorax should be considered when lenvatinib is used in patients with lung metastasis.
一名63岁男性被诊断为间变性甲状腺癌伴多发肺转移，并接受了乐伐替尼治疗。乐伐替尼治疗第34天的随访计算机断层扫描显示气胸。通过胸腔引流，气胸暂时得到改善。然而，为治疗气胸复发进行了胸膜固定术。恶性肿瘤化疗期间的气胸被认为是一种相对罕见的并发症。该病例是乐伐替尼治疗期间可能发生气胸的首例记录。在肺转移患者中使用乐伐替尼时，应考虑到可能发生气胸。
